Supply Chain Intelligence

Immix Biopharma, Inc. Supply Chain

IMMX supply chain intelligence for Immix Biopharma, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

IMMX ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

7Suppliers
0Customers
3Debt Items
0Related Chains

Immix Biopharma, Inc. Suppliers

TickerNameConfidenceEvidence
U-S-MEDICAL-RESEARCH-FOUNDATION U-S-MEDICAL-RESEARCH-FOUNDATION 92% In August 2024, the Company entered into a Patent License Agreement with a U.S. medical research foundation pursuant to which the Company was granted certain exclusive and nonexclusive licenses and s…
BIRAD-RESEARCH-AND-DEVELOPMENT-COMPANY-LTD BIRAD-RESEARCH-AND-DEVELOPMENT-COMPANY-LTD 90% Pursuant to the Agreement, Nexcella paid the Licensors an upfront fee of $1,500,000 in December 2022.
HADASIT-MEDICAL-RESEARCH-SERVICES-DEVELOPMENT-LT HADASIT-MEDICAL-RESEARCH-SERVICES-DEVELOPMENT-LT 90% Pursuant to the Agreement, Nexcella paid the Licensors an upfront fee of $1,500,000 in December 2022.
NEXCELLA-INC NEXCELLA-INC 90% Research and License Agreement entered into on November 27, 2022 by and between Nexcella, Inc. (formerly Immix Biopharma Cell Therapy, Inc.), Hadasit Medical Research Services & Development, Ltd. and…
THIRD-PARTY-CONTRACT-MANUFACTURERS THIRD-PARTY-CONTRACT-MANUFACTURERS 80% We do not have any long-term manufacturing and supply agreements with our third-party contract manufacturers, but we enter into specific contracts on an as needed basis for individual batch productio…
THIRD-PARTY-CONTRACT-ORGANIZATIONS THIRD-PARTY-CONTRACT-ORGANIZATIONS 80% The Company has made certain accounting policy elections whereby it (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12-months or less) and (…
CONTRACT-RESEARCH-ORGANIZATIONS CONTRACT-RESEARCH-ORGANIZATIONS 70% The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including... contract manufa…

Immix Biopharma, Inc. Customers

No clients on recordNo downstream customers found in our database for Immix Biopharma, Inc..

Immix Biopharma, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
IMMX-DEBT Debt stack $1.0M 90% Market cache reports total debt of $1.0M.
IMMX-DEBT-10240 Warrants outstanding: 31500 90% xbrl warrant detail from xbrl 2026-03-31.
IMMX-DEBT-10241 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.

Immix Biopharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Immix Biopharma, Inc..

Immix Biopharma, Inc. Ownership

HolderNameConfidenceEvidence
IMMX-OWNER-JANUS-HENDERSON-GROUP-PLC JANUS HENDERSON GROUP PLC 90% 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 77 tracked holders.

Immix Biopharma, Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.
View IMMX supply chain intel →

Explore the full interactive supply chain map for Immix Biopharma, Inc..

Open IMMX supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map